A. Simon Lynch
Janssen Pharmaceutica
24 Papers
257 Citations
A. Simon Lynch is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Staphylococcus aureus & Medicine. The author has an hindex of 15, co-authored 21 publications. Previous affiliations of A. Simon Lynch include Johnson & Johnson Pharmaceutical Research and Development.
Chat about Author
Papers
Bacterial and Fungal Biofilm Infections
TL;DR: This review summarizes the existing data relating to the nature, prevalence, and treatment of biofilm-associated infections and highlights experimental approaches and therapies that are being pursued toward more effective treatments.
470
Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007–09
Todd A. Davies,Anne Marie Queenan,Brian J. Morrow,Wenchi Shang,K. Amsler,Wenping He,A. Simon Lynch,Chris M. Pillar,Robert K. Flamm +8 more
TL;DR: Dorbenem and meropenem were more active than imipenem against Enterobacteriaceae and P. aeruginosa, and Carbapenem resistance mechanisms included serine carbapenemsases, elevated AmpC activity, efflux and porin deficiencies occurring mostly in P.aeruginose.
101
Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections
TL;DR: This review focuses on efforts towards the discovery and development of antibody-based biologic agents and their potential as clinical agents in the management of serious S. aureus infections.
97
Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010☆☆☆
Anne Marie Queenan,Chris M. Pillar,Jennifer Deane,Daniel F. Sahm,A. Simon Lynch,Robert K. Flamm,Janet Peterson,Todd A. Davies +7 more
TL;DR: Trends in the distribution and prevalence of the MDR phenotype in Acinetobacter spp.
82
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
Gregory T. Robertson,Eric J. Bonventre,Timothy B Doyle,Qun Du,Leonard R. Duncan,Timothy W. Morris,Eric D. Roche,Dalai Yan,A. Simon Lynch +8 more
TL;DR: In this paper, the authors describe mode-of-action studies with Staphylococcus aureus of CBR-2092, a novel hybrid that combines the rifamycin SV and 4H-4-oxo-quinolizine pharmacophores.
74